Challenges in Use of Generic DMTs for Treatment of MS
Experts in neurology provide insight on challenges that arise with the use of generic DMTs in RRMS treatment, such as cost to the patient.
Use of Generic DMTs in Clinical Practice in RRMS
Ahmed Zayed Obeidat MD, PhD; Ravi Dukkipati, MD; and Gabriel Pardo, MD, FAAN, comment on the use of generic DMTs in the treatment of RRMS, highlighting efficacy and safety data as well as level of equivalence to brand name treatments.
Treatment Options for a Patient With RRMS and Psoriasis
Expert neurologists discuss treatment options for a patient with comorbid autoimmune diseases, relapsing/remitting multiple sclerosis, and psoriasis.
Patient Case #2: 36-Year-Old Female With RRMS With Lesions in the Spine and Brain
Ravi Dukkipati, MD, and Gabriel Pardo, MD, FAAN, review the use of rituximab and other disease-modifying therapies in a patient with an established diagnosis of relapsing/remitting multiple sclerosis.
Switching DMTs in Patients With RRMS
Ahmed Zayed Obeidat MD, PhD; Ravi Dukkipati, MD; and Gabriel Pardo, MD, FAAN, discuss a patient case with relapsing/remitting multiple sclerosis progression and share considerations for switching treatment.
Patient Case #1: 37-Year-Old Female With RRMS
Expert neurologists review treatment options for a young female with relapsing remitting multiple sclerosis (RRMS).
Generic DMTs as First-Line Treatment in RRMS
Ahmed Zayed Obeidat MD, PhD; Ravi Dukkipati, MD; and Gabriel Pardo, MD, FAAN, consider reasons to use generic disease-modifying therapies (DMTs) as a first-line therapy in the treatment of relapsing remitting multiple sclerosis (RRMS).
Treatment Selection in RRMS
Experts in neurology highlight factors that lead them to choose certain therapies to treat relapsing remitting multiple sclerosis (RRMS), such as high efficacy in clinical trials.
FDA Approval Process for RRMS Therapies
Gabriel Pardo, MD, FAAN, describes the process that generic RRMS medications have to go through to be approved by the FDA, highlighting the abbreviated new drug application [ANDA] process.
Generic Disease-Modifying Therapies (DMTs) in RRMS
Expert neurologists review availability of generic disease-modifying therapies [DMTs] and the effectiveness of reduced cost to the patient with RRMS
Unmet Needs in the RRMS Treatment Landscape
Ravi Dukkipati, MD, and Gabriel Pardo, MD, FAAN, discuss barriers in accessing treatment for patients with RRMS, as well as a lack of appropriate biomarkers to monitor disease progression.
Advances in the Management of Relapsing-Remitting Multiple Sclerosis (RRMS)
Experts in neurology review recent advances in the treatment landscape of relapse-remitting multiple sclerosis (RRMS) and the ever-present challenge of tailoring treatment to individual patients.
2 Clarke Drive Cranbury, NJ 08512